Researchers at UBC’s Okanagan campus have developed a new and improved method to judge the effectiveness of experimental therapies for neurodegeneration—the progressive loss of neurons.
“Neurons—or nerve cells—are hugely important to our daily lives,” said post-doctoral fellow Aaron Johnstone and study lead author. “These specialized cells collect and process the large amounts of information that enter our bodies via our senses, control our muscles and organs, and form our thoughts and memories. When these cells become unhealthy, it leads to diseases like Alzheimer’s and Parkinson’s, ALS, glaucoma and chronic pain.”
Johnstone says his study uses the first automated test specifically designed for measuring degeneration of sensory neurons grown in a lab.
“The variability in nerve cell lengths, densities and shapes have traditionally made it difficult to reliably analyze their health,” said Johnstone. “This, in turn, has generated confusion about the effectiveness of potential pharmacological or genetic treatments.”
Using the new approach, which is software-assisted, the research team were able to measure nerve cell densities more accurately.
To do this the team grew nerve cells in a lab environment, and after establishing healthy neurons researchers mimicked the conditions that cause neurodegeneration. Neuron loss was then captured using fluorescent microcopy—a process that makes the tiny cells easier to see—and analyzed using a computer algorithm.
Johnstone suggests that objective measurement is essential to the process of developing new medicines.
“This procedure makes evaluating new treatment options, like drugs or gene therapies, far more accurate and trustworthy,” Johnstone said.
The study is a collaboration between UBC Okanagan Vice Principal of Research Phil Barker’s lab and Robin Hallett, research fellow at Toronto’s Sick Kids Hospital.
The study, published in PLoS One was supported by funds from the Canadian Institutes of Health Research and the Health Research Fund of Quebec.
To report a typo, email: